Sugentech, Inc.
Founded in 2011 and KOSDAQ-listed in 2019, Sugentech develops multiplex immunoblot, point-of-care, and digital healthcare diagnostics.
As of 2026-10-10, Sugentech, Inc. has 157 Korean MFDS device approvals, 1 US FDA clearance/approval, 5 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2011 and listed on KOSDAQ in 2019, Sugentech is an in-vitro diagnostics company spanning multiplex immunoblot, point-of-care testing (POCT), and digital healthcare. It offers the SGTi-Allergy Screen PLUS, which tests for 120 allergens, the SGTi-ANA Screen 14S autoimmune reagent with its fully automated S-Blot 3 system, the SGTi-flex COVID-19 Ag rapid antigen kit, the INCLIX quantitative diagnostic device for cardiovascular disease, diabetes, and hormones, and pregnancy, ovulation, and hormone test kits under its Surearly women's health brand. It holds multiple registered patents, including an automated analysis system (KR 10-2175186), a specimen tube holder (KR 10-1999604), a strip lot management process (KR 10-2241251), and a time-resolved fluorescence signal analyzer (KR 10-2126694).
Products & technology
- SGTi-Allergy Screen (PLUS/60)Testing for up to 120 allergens
- SGTi-ANA Screen 14SAutoimmune disease (ANA) diagnosis
- S-Blot series (S-Blot 2/2 Easy/2 PLUS, S-Blot 3/3 PLUS, Tenfly Auto)Semi- and fully automated multiplex immunoblot analysis systems
- SGTi-flex series (COVID-19 Ag, Influenza A&B, Dengue, Mycoplasma, etc.)Rapid antigen testing for infectious diseases
- INCLIX / INCLIX F-100Quantitative diagnosis of cardiovascular disease, diabetes, and hormones (TRF fluorescence-based)
- Surearly test kits and smart devicesHome testing for pregnancy, ovulation, menopause, and hormones
- Hormone-personalized cosmetics and health functional foodsDiagnostic-data-based health and beauty solutions
Regulatory approvals
data.go.kr · openFDA157 Korean MFDS device approvals · 2007–2026 / 1 US FDA 510(k) · 2016
- MFDSClinical IVD strip for endocrine, related to pregnant2026-01-07Product approval · Class 2체외 제인 26-4015 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2025-12-15Product approval · Class 3체외 제허 25-840 호
- MFDSIVD Reagents for pregnancy/childbirth hormone and protein tests2025-12-01Product approval · Class 2체외 제인 25-5116 호
- MFDSIVD Reagents for pregnancy/childbirth hormone and protein tests2025-11-19Product approval · Class 2체외 제인 25-5074 호
- MFDSIVD reagents for bone and mineral metabolite measurement test2025-10-27Product approval · Class 2체외 제인 25-4989 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2025-09-17Product approval · Class 3체외 제허 25-647 호
- MFDSIVD Reagents for thyroid function hormone tests2025-09-09Product approval · Class 2체외 제인 25-4850 호
- MFDSIVD Reagents for thyroid function hormone tests2025-07-08Product approval · Class 2체외 제인 25-4604 호
- MFDSIVD reagents for allergy test2025-05-20Product approval · Class 2체외 제인 25-4431 호
- MFDSIVD strip for endocrine self test2025-04-30Product approval · Class 2체외 제인 25-4366 호
- MFDSIVD Reagents for thyroid function hormone tests2025-04-30Product approval · Class 2체외 제인 25-4365 호
- MFDSIVD Reagents for thyroid function hormone tests2025-04-30Product approval · Class 2체외 제인 25-4364 호
Show 68 more
- MFDSIVD strip for endocrine self test2024-12-31Product approval · Class 2체외 제인 24-1199 호
- MFDSGeneral gene amplificator, nucleic acid, without fluorescence meter2024-12-24Product approval · Class 1체외 제신 24-1625 호
- MFDSIVD reagents for diagnostic blood coagulation test2024-11-19Product approval · Class 3체외 제허 24-815 호
- MFDSIVD Reagents for thyroid function hormone testsRevoked2024-11-01Product approval · Class 2체외 제인 24-984 호
- MFDSIVD Reagents for pregnancy/childbirth hormone and protein tests2024-10-31Product approval · Class 2체외 제인 24-979 호
- MFDSIVD reagents for inflammatory tests2024-10-29Product approval · Class 2체외 제인 24-972 호
- MFDSIVD reagents for diabetes mellitus2024-10-25Product approval · Class 2체외 제인 24-965 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2024-10-21Product approval · Class 3체외 제허 24-709 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2024-10-17Product approval · Class 3체외 제허 24-703 호
- MFDSIVD strip for endocrine self test2024-10-08Product approval · Class 2체외 제인 24-917 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2024-09-23Product approval · Class 3체외 제허 24-647 호
- MFDSImmunoabsorbance analyzer2024-07-22Product approval · Class 1체외 제신 24-923 호
- MFDSIVD reagents for urine chemistry2024-07-03Product approval · Class 2체외 제인 24-664 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2024-07-03Product approval · Class 3체외 제허 24-450 호
- MFDSIVD reagents for allergy test2024-06-07Product approval · Class 2체외 제인 24-569 호
- MFDSIVD strip for endocrine self test2024-04-18Product approval · Class 2체외 제인 24-403 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2024-04-08Product approval · Class 3체외 제허 24-248 호
- MFDSIVD reagents for inflammatory tests2024-01-30Product approval · Class 2체외 제인 24-116 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2024-01-24Product approval · Class 3체외 제허 24-62 호
- MFDSIVD reagents for allergy test2024-01-09Product approval · Class 2체외 제인 24-33 호
- MFDSIVD reagents for diabetes mellitus2024-01-04Product approval · Class 2체외 제인 24-16 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2023-12-13Product approval · Class 3체외 제허 23-1133 호
- MFDSImmunoabsorbance analyzer2023-12-06Product approval · Class 1체외 제신 23-1729 호
- MFDSIVD reagents for allergy test2023-11-20Product approval · Class 2체외 제인 23-5263 호
- MFDSEndocrinology/hormone analyzer for self test, related to pregnancy2023-10-10Product approval · Class 2체외 제인 23-5146 호
- MFDSImmunoabsorbance analyzer2023-09-08Product approval · Class 1체외 제신 23-1355 호
- MFDSImmunoabsorbance analyzer2023-06-19Product approval · Class 1체외 제신 23-942 호
- MFDSIVD reagents for inflammatory testsRevoked2023-06-09Product approval · Class 2체외 제인 23-4795 호
- MFDSIVD reagents for cardiac marker2023-05-08Product approval · Class 3체외 제허 23-565 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2023-04-18Product approval · Class 3체외 제허 23-510 호
- MFDSIVD reagents for allergy test2023-03-31Product approval · Class 2체외 제인 23-4601 호
- MFDSIVD strip for endocrine self test2023-03-24Product approval · Class 2체외 제인 23-4586 호
- MFDSIVD strip for endocrine self test2023-03-24Product approval · Class 2체외 제인 23-4584 호
- MFDSIVD strip for endocrine self test2023-03-24Product approval · Class 2체외 제인 23-4583 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2023-02-06Product approval · Class 3체외 제허 23-86 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological methodRevoked2022-12-05Product approval · Class 3체외 제허 22-822 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2022-12-05Product approval · Class 3체외 제허 22-820 호
- MFDSIVD strip for endocrine self test2022-11-03Product approval · Class 2체외 제인 22-4841 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2022-09-29Product approval · Class 3체외 제허 22-652 호
- MFDSImmunoabsorbance analyzer2022-09-06Product approval · Class 1체외 제신 22-1251 호
- MFDSFluorimetric immunoassay analyzer(FIA), stationary2022-06-24Product approval · Class 1체외 제신 22-866 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2022-06-10Product approval · Class 3체외 제허 22-377 호
- MFDSIVD reagents for autoimmune disease2022-03-11Product approval · Class 2체외 제인 22-4191 호
- MFDSImmunoabsorbance analyzer2022-02-24Product approval · Class 1체외 제신 22-259 호
- MFDSIVD reagent for infectious disease, immunological method2022-02-04Product approval · Class 3체외 제허 22-73 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2021-12-06Product approval · Class 3체외 제허 21-978 호
- MFDSIVD reagents for autoimmune disease2021-10-28Product approval · Class 2체외 제인 21-4918 호
- MFDSIVD strip for endocrine self test2021-06-29Product approval · Class 2체외 제인 21-4559 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2021-06-09Product approval · Class 3체외 제허 21-465 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2021-06-08Product approval · Class 3체외 제허 21-452 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2021-05-25Product approval · Class 3체외 제허 21-407 호
- MFDSIVD reagents for diagnostic blood coagulation test2021-05-14Product approval · Class 3체외 제허 21-379 호
- MFDSIVD strip for endocrine self test2021-04-21Product approval · Class 2체외 제인 21-4327 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2021-04-16Product approval · Class 3체외 제허 21-303 호
- MFDSIVD strip for endocrine self test2021-01-27Product approval · Class 2체외 제인 21-4053 호
- MFDSEndocrinology/hormone analyzer for self test, related to pregnancy2020-12-21Product approval · Class 2체외 제인 20-5127 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2020-12-18Product approval · Class 3체외 제허 20-1112 호
- MFDSGeneral Calibrators, controls or standards, classⅢ, for clinical immunology, not a component of specific kit, wide use2020-12-16Product approval · Class 3체외 제허 20-1095 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2020-10-29Product approval · Class 3체외 제허 20-920 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2020-08-18Product approval · Class 3체외 제허 20-675 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2020-08-14Product approval · Class 3체외 제허 20-664 호
- MFDSTool for specimens2020-08-13Product approval · Class 1수신 20-1928 호
- MFDSImmunoabsorbance analyzer2020-07-16Product approval · Class 1체외 제신 20-1085 호
- MFDSIVD reagents for allergy test2020-06-29Product approval · Class 2체외 제인 20-4571 호
- MFDSFluorimetric immunoassay analyzer(FIA), stationary2020-06-26Product approval · Class 1체외 제신 20-977 호
- MFDSCapillary blood collection tube2020-04-10Product approval · Class 1제신 20-503 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2020-03-24Product approval · Class 3체외 제허 20-215 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2020-03-24Product approval · Class 3체외 제허 20-214 호
Showing the 80 most recent of 158 records.
R&D and key agreements
Source: DART corporate disclosure다중면역블롯 자동분석시스템 특허 · 등록/출원 · Holds patents for an automated analysis system (KR 10-2175186), strip temperature control (application 10-2021-0193129), specimen tube holder (KR 10-1999604), and strip lot management process (KR 10-2241251)
INCLIX 시간분해형광 분석기술 · 등록 · Holds a patent for a time-resolved fluorescence signal analyzer (KR 10-2126694)
Publications
PubMed · affiliation-matched- Correction: Oligomeric states of ASC specks regulate inflammatory responses by inflammasome in the extracellular space.
Cell death discovery · 2023-07 · Yu TG, Cha JS, Kim G 외 6
- Oligomeric states of ASC specks regulate inflammatory responses by inflammasome in the extracellular space.
Cell death discovery · 2023-04 · Yu TG, Cha JS, Kim G 외 6
- Diagnostic Models for Screening of Periodontitis with Inflammatory Mediators and Microbial Profiles in Saliva.
Diagnostics (Basel, Switzerland) · 2020-10 · Lee J, Lee JB, Song HY 외 8
- Optimized Expression, Purification, and Rapid Detection of Recombinant Influenza Nucleoproteins Expressed in Sf9 Insect Cells.
Journal of microbiology and biotechnology · 2018-10 · Yoon SJ, Park YJ, Kim HJ 외 4
- Wound healing potential of antibacterial microneedles loaded with green tea extracts.
Materials science & engineering. C, Materials for biological applications · 2014-09 · Park SY, Lee HU, Lee YC 외 9
Patents
KIPRIS · applicant-matchedPublished · 2024-12 · Application 1020240182200
US · Published · 2024-11 · Application 18939545
PCT · Published · 2024-10 · Application PCT/KR2024/015503
Published · 2023-12 · Application 1020230184433
Registered · 2023-12 · Application 1020230179696
PCT · Published · 2023-11 · Application PCT/KR2023/017893
Registered · 2023-10 · Application 1020230142674
PCT · Published · 2023-06 · Application PCT/KR2023/008925
Registered · 2023-03 · Application 1020230035050
Registered · 2023-01 · Application 1020230006217
Show 73 more patents
EP · Published · 2022-12 · Application 22916484.3
CN · Published · 2022-12 · Application 202280086948.6
PCT · Published · 2022-12 · Application PCT/KR2022/019449
Rejected · 2022-11 · Application 1020220161979
Rejected · 2022-11 · Application 1020220161980
Registered · 2022-10 · Application 1020220126212
PCT · Published · 2022-08 · Application PCT/KR2022/012947
PCT · Published · 2022-08 · Application PCT/KR2022/012953
Registered · 2021-12 · Application 1020210193129
Withdrawn · 2021-11 · Application 1020210149314
Registered · 2021-09 · Application 1020210125472
Registered · 2021-08 · Application 1020210114937
Registered · 2021-08 · Application 1020210114939
Registered · 2021-04 · Application 2020210001375
CN · Published · 2021-04 · Application 202180031841.7
US · Published · 2021-04 · Application 17922578
PCT · Published · 2021-04 · Application PCT/KR2021/005479
EP · Registered · 2020-07 · Application 20846197.0
PCT · Published · 2020-07 · Application PCT/KR2020/008903
US · Published · 2020-06 · Application 16910544
Registered · 2020-05 · Application 1020200065223
PCT · Published · 2019-12 · Application PCT/KR2019/018497
Registered · 2019-12 · Application 1020190174381
PCT · Published · 2019-12 · Application PCT/KR2019/016923
Registered · 2019-11 · Application 1020190145966
Registered · 2019-10 · Application 1020190137400
Registered · 2019-07 · Application 1020190090986
US · Registered · 2019-07 · Application 17259232
PCT · Published · 2019-07 · Application PCT/KR2019/008507
EP · Published · 2019-04 · Application 19793902.8
CN · Published · 2019-04 · Application 201980028108.2
US · Published · 2019-04 · Application 17050081
PCT · Published · 2019-04 · Application PCT/KR2019/005079
Registered · 2019-04 · Application 1020190043268
Rejected · 2018-12 · Application 1020180167278
EP · Published · 2018-12 · Application 18892688.5
CN · Published · 2018-12 · Application 201880083123.2
US · Published · 2018-12 · Application 16955934
PCT · Published · 2018-12 · Application PCT/KR2018/016434
JP · Published · 2018-12 · Application 32555001
PCT · Published · 2018-12 · Application PCT/KR2018/015994
CN · Published · 2018-11 · Application 201880077994.3
EP · Registered · 2018-11 · Application 18879821.9
PCT · Published · 2018-11 · Application PCT/KR2018/013925
EP · Registered · 2018-10 · Application 18897733.4
CN · Published · 2018-10 · Application 201880084478.3
PCT · Published · 2018-10 · Application PCT/KR2018/012147
Registered · 2018-07 · Application 1020180080510
Registered · 2018-06 · Application 1020180063620
Registered · 2018-04 · Application 1020180048482
Registered · 2017-12 · Application 1020170182705
Registered · 2017-12 · Application 1020170179716
Registered · 2017-11 · Application 1020170151547
PCT · Published · 2017-10 · Application PCT/KR2017/012156
Rejected · 2017-08 · Application 1020170108177
Registered · 2016-04 · Application 1020160043146
Registered · 2016-01 · Application 1020160008609
Expired · 2015-07 · Application 1020150105009
Registered · 2015-04 · Application 1020150058943
Expired · 2015-03 · Application 1020150033566
US · Registered · 2014-05 · Application 14894985
PCT · Published · 2014-04 · Application PCT/KR2014/003026
CN · Published · 2014-04 · Application 201480023212
US · Registered · 2014-04 · Application 14786225
EP · Registered · 2014-04 · Application 14788103.1
PCT · Published · 2014-04 · Application PCT/KR2014/002914
Registered · 2014-04 · Application 1020140039299
Registered · 2014-03 · Application 1020140032730
Registered · 2014-01 · Application 1020140006301
Registered · 2013-05 · Application 1020130057684
Registered · 2012-10 · Application 1020120112015
EP · Registered · 2012-07 · Application 12175714.0
Withdrawn · 2012-04 · Application 1020120040788
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive2
- OpenAIOAI-SearchBot111
- GoogleGoogleOther17
- PerplexityPerplexityBot6
- AnthropicClaudeBot2
- MicrosoftBingbot1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Sugentech, Inc. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies approved for the same productsMedical Devices
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.
KOSDAQ-listed point-of-care immunodiagnostics company supplying diagnostic cartridges and the ichroma/AFIAS instrument series.
GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.
Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.
Founded in 1987 and listed on KOSDAQ in 2000, NanoenTek develops Lab-On-a-Chip in-vitro diagnostic devices and life science instruments.
KOSDAQ-listed IVD company producing COVID-19 and HIV point-of-care diagnostic reagents alongside rubber products and entertainment businesses.
KOSDAQ-listed IVD company producing time-resolved fluorescence immunodiagnostic products under the Exdia TRF brand.
Dong-A ST, spun off from Dong-A Socio Holdings in 2013 and KOSPI-listed, makes prescription drugs like Growtropin, Stillen, and Bacchus.
KOSDAQ-listed in-vitro diagnostics company selling PROTIA Allergy-Q allergy diagnostic products domestically and in 80+ countries.
Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.
Founded in 2002 and KOSDAQ-listed in 2013, Access Bio develops rapid diagnostic tests for malaria, COVID-19, and other infectious diseases.
Holds manufacturing approvals for 42 point-of-care diagnostic reagents and devices in the IVD market.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition